Challenges in Development of Nanoparticle-Based Therapeutics
Top Cited Papers
Open Access
- 10 March 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 14 (2), 282-295
- https://doi.org/10.1208/s12248-012-9339-4
Abstract
In recent years, nanotechnology has been increasingly applied to the area of drug development. Nanoparticle-based therapeutics can confer the ability to overcome biological barriers, effectively deliver hydrophobic drugs and biologics, and preferentially target sites of disease. However, despite these potential advantages, only a relatively small number of nanoparticle-based medicines have been approved for clinical use, with numerous challenges and hurdles at different stages of development. The complexity of nanoparticles as multi-component three dimensional constructs requires careful design and engineering, detailed orthogonal analysis methods, and reproducible scale-up and manufacturing process to achieve a consistent product with the intended physicochemical characteristics, biological behaviors, and pharmacological profiles. The safety and efficacy of nanomedicines can be influenced by minor variations in multiple parameters and need to be carefully examined in preclinical and clinical studies, particularly in context of the biodistribution, targeting to intended sites, and potential immune toxicities. Overall, nanomedicines may present additional development and regulatory considerations compared with conventional medicines, and while there is generally a lack of regulatory standards in the examination of nanoparticle-based medicines as a unique category of therapeutic agents, efforts are being made in this direction. This review summarizes challenges likely to be encountered during the development and approval of nanoparticle-based therapeutics, and discusses potential strategies for drug developers and regulatory agencies to accelerate the growth of this important field.Keywords
This publication has 88 references indexed in Scilit:
- Minireview: Nanoparticles and the Immune SystemEndocrinology, 2010
- Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticlesJournal of Controlled Release, 2010
- Evaluation of Efficacy, Biodistribution, and Inflammation for a Potent siRNA Nanoparticle: Effect of Dexamethasone Co-treatmentMolecular Therapy, 2010
- Nanomedicine in pulmonary deliveryInternational Journal of Nanomedicine, 2009
- Nanoparticle-Mediated IgE−Receptor Aggregation and Signaling in RBL Mast CellsJournal of the American Chemical Society, 2009
- Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNSBMC Neuroscience, 2008
- Tumour-targeted nanomedicines: principles and practiceBritish Journal of Cancer, 2008
- Preclinical Studies To Understand Nanoparticle Interaction with the Immune System and Its Potential Effects on Nanoparticle BiodistributionMolecular Pharmaceutics, 2008
- Vesicle size and stability of biomimetic liposomes from 3′-sulfo-Lewis a (SuLea) containing glycolipidsColloids and Surfaces B: Biointerfaces, 2007
- Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivoProceedings of the National Academy of Sciences of the United States of America, 2006